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The Drosophila F Box Protein Archipelago
Regulates dMyc Protein Levels In Vivo
the oncogenic properties of myc genes are conserved
in other organisms.
Myc deregulation in cancer occurs by a variety of
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1Massachusetts General Hospital Cancer Center mechanisms [1]. In some cancers, notably lymphomas,
mutations found within the Myc protein have beenBuilding 149, 13th Street
Charlestown, Massachusetts 02129 shown to increase its stability [9, 10]. Myc protein is
normally turned over rapidly in vivo and in cultured cells
has a half-life of 20–30 min, and several studies have
shown that Myc protein is subject to ubiquitin-depen-Summary
dent proteasomal degradation [1]. Ubiquitination of Myc
in turn appears to be regulated by phosphorylation atBackground: The Myc oncoprotein is an important regu-
two distinct sites in the protein’s amino-terminal portion,lator of cellular growth in metazoan organisms. Its levels
Threonine 58 (Thr58) and Serine 62 (Ser62) [11–14]. Evi-and activity are tightly controlled in vivo by a variety
dence suggests that MAP kinase mediates phosphoryla-of mechanisms. In normal cells, Myc protein is rapidly
tion of Ser62 and that this stabilizes c-Myc. Phosho-degraded, but the mechanism of its degradation is not
Ser62 may be required for subsequent phosphorylationwell understood.
of Thr58 by glycogen-synthase kinase 3 (GSK3), whichResults: Here we present genetic and biochemical evi-
promotes the ubiquitination and degradation of c-Mycdence that Archipelago (Ago), the F box component of
[15]. Significantly, Thr58Ile is the most common c-Mycan SCF-ubiquitin ligase and the Drosophila ortholog of
mutation in Burkitt’s lymphoma [1] and is known to stabi-a human tumor suppressor, negatively regulates the lev-
lize Myc considerably [9, 10]. These observations sug-els and activity of Drosophila Myc (dMyc) protein in vivo.
gest that phosphorylation of Thr58 by GSK3 generatesMutations in archipelago (ago) result in strongly elevated
a motif that facilitates the interaction of Myc with adMyc protein levels and increased tissue growth. Ge-
ubiquitin ligase that restricts Myc levels and activitynetic interactions indicate that ago antagonizes dMyc
in vivo. Currently, the identity of the ubiquitin ligase thatfunction during development. Archipelago binds dMyc
promotes Myc degradation has not been firmly estab-and regulates its stability, and the ability of Ago to bind
lished in any organism.dMyc in vitro correlates with its ability to inhibit dMyc
Here we implicate the Drosophila F box protein Archi-accumulation in vivo.
pelago (Ago) in the degradation of Drosophila MycConclusions: Our data indicate that archipelago is an
(dMyc). We find that Ago binds dMyc, and impairmentimportant inhibitor of dMyc in developing tissues. Be-
of Ago function in vivo stabilizes dMyc, resulting in mark-cause archipelago can also regulate Cyclin E levels and
edly elevated Myc levels, and promotes cell growth.Notch activity, these results indicate how a single F box
Recent evidence indicates that the Fbw7/hCDC4 tumorprotein can be responsible for the degradation of key
suppressor protein, which is the human ortholog of Ago,components of multiple pathways that control growth
also inhibits c-Myc accumulation by promoting its deg-and cell cycle progression.
radation [16]. Because Ago proteins also regulate Cyclin
E levels [17–19] and Notch pathway activity (K.H.M.,
Introduction unpublished observations and reviewed in [20]), our
findings suggest a mechanism by which the levels of
myc genes encode basic-helix-loop-helix-zipper (bHLHZ) Cyclin E and dMyc and the activity of the Notch pathway
domain transcription factors that dimerize with Max fam- can be coordinately regulated by a shared degradation
ily proteins to promote cell growth and proliferation in pathway.
metazoan organisms (reviewed in [1, 2]). The Myc-Max
complex is implicated in the transcriptional regulation
of many genes that are required for cell growth and Results
metabolism; such genes include those for translation
initiation factors and ribosomal components [2–4]. The Loss of archipelago Accelerates Both Growth
role of Myc in promoting growth is likely to contribute and Cell Cycle Progression
to its role as an oncoprotein in a wide variety of human archipelago (ago) mutations lead to overproliferation of
tumor types [5]. myc overexpression also promotes tu- mutant tissue in the developing Drosophila eye, and
morigenesis in mice and zebrafish [6–8], indicating that we have shown that ago mutant cells express elevated
levels of Cyclin E protein and are delayed in their exit
from the cell cycle [17]. The Ago protein, as well as its*Correspondence: kmoberg@cellbio.emory.edu
2 These authors contributed equally to this work. human ortholog Fbw7/hCDC4, is the F box component
3 Present address: Department of Cell Biology, Emory University of an SCF E3-ubiquitin ligase, and Ago binds Cyclin E
School of Medicine, Whitehead Biomedical Research Building, 615 and targets it for ubiquitination and subsequent degra-
Michael Street, Atlanta, Georgia 30322.
dation [17–19]. The overgrowth of ago mutant tissue4 Present address: Department of Molecular and Cell Biology, Uni-
implies that the ago mutant cells collectively grow (i.e.,versity of California, Berkeley, 142 Life Sciences Addition #3200,
Berkeley California 94720. accumulate mass) at an accelerated rate in comparison
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Figure 1. ago Mutant Cells Have a Growth
Advantage
Cell numbers in wing disc clones of the (A)
ago mutant (gray bars) or (C) FRT80B chro-
mosome (gray bars), in each case compared
to control twin spots (black bars). Individual
clone pairs generated from the same recom-
bination event are ordered in increasing num-
ber of mutant cells. Data from two popula-
tions of wing discs induced at time zero (a
single heat shock treatment 48 hr AED) was
collected 48, 72, 96, and 120 hr later and
pooled. The inset in (A) shows an example of
an ago clone/twin spot pair. Adult eyes show
that (B) ago mutant (white) tissue overgrows
compared to wild-type (red) tissue, while (D)
FRT80B tissue does not. Forward scatter
(FSC) profiles indicating that the cell size of
control cells (gray line), ([E], black line) ago
mutant cells, and ([F], black line) FRT80B cells
are comparable. Inset values are the ratio of
mean FSC values of control cells compared
to ago cells or FRT80B cells. Indicated dou-
bling times (D.T.) were calculated with data
from the 72 hr time point of a single induction.
to wild-type cells (Figures 1B and 1D). Because Dro- cells, we conducted two different interaction screens
by using the Ago F box/WD domain (see comment insophila Cyclin E has been shown to promote S phase
entry but not growth [21], the increased growth of ago Molecular Biology section of the Experimental Proce-
dures). By mass spectrometric analysis of proteins thatmutant cells suggests that there are other Ago sub-
strates that promote cell growth. coprecipitate with Ago, we identified peptides derived
from a number of different SCF components, includingTo examine the growth properties of ago mutant cells,
we generated marked pairs of ago mutant clones and Cullins and Skp proteins. At a lower frequency, we also
recovered peptides derived from putative SCFAgo sub-wild-type sister clones (twin spots) in the developing
larval wing imaginal disc. ago mutant clones in the wing strates, including the Drosophila ortholog of the Myc
transcription factor (dMyc). In addition to multiple SCF(Figure 1A) and the eye (Figure 1B) are consistently larger
and contain more cells than their respective twin spots components, a single clone of dMyc was also recovered
in a yeast two-hybrid screen for proteins that physically(labeled control). In contrast, pairs of clones and twin
spots generated from the FRT80B parent chromosome interact with the F box/WD repeat region of Ago.
Because dMyc has been shown to promote growthdo not display differences in either cell number (Figure
1C) or clone size (Figure 1D and data not shown). The in imaginal-disc cells [22], the role of Ago in regulating
dMyc levels was examined further. Eye imaginal discsincreased cell number in ago clones indicates that ago
mutant cells divide more frequently over a fixed period containing ago mutant clones were stained with an anti-
dMyc monoclonal antibody (Figures 2A–2F). dMyc pro-of time than do control cells and thus have a shortened
cell cycle duration. Indeed, the calculated length of an tein is strongly elevated in ago mutant cells, both in
third-larval-instar eye discs (Figures 2A–2C) and in earlyaverage cell cycle in ago cells is approximately 15%
shorter than in control cells (Figure 1). However, flow- pupal-phase eye discs (Figures 2D–2F). Increased dMyc
staining is observed in ago cells found throughout thecytometric analysis indicates that ago cells are not de-
creased in size (Figures 1E and 1F). These observations larval eye disc and antennal discs. In the pupal eye disc,
dMyc levels are especially high in the clusters of nuclei ofindicate that ago cells coordinately accelerate rates of
cell growth and cell division such that normal cell size the bristle cell complex (Figure 2E, arrow). Immunoblot
analysis also indicates that dMyc levels are highly ele-is maintained.
vated in extracts of ago mutant discs compared to
FRT80B control discs (Figure 2G). In this experiment, theago Cells Have Elevated dMyc Levels
To identify an SCFAgo ubiquitin ligase substrate that twinspots carry two copies of a strong Minute mutation
[M(3)] that dramatically impairs their growth such thatcould explain the accelerated growth of ago mutant
ago Inhibits dMyc Accumulation in Drosophila
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Figure 2. Loss of ago Deregulates dMyc Pro-
tein Levels and Results in Increased Expres-
sion of a dMyc Target Gene In Vivo
Levels of dMyc protein (red) in (A–C) third-
instar and (D–F) 24 hr pupal eye discs that
contain ago mutant clones marked by the ab-
sence of GFP (green) in (A) and (C) or by the
absence of -galactosidase (blue) in (D) and
(F). Images in (C) and (F) are merges from (A)
and (B) and from (D) and (E), respectively.
Arrowheads in (A)–(C) denote the morphoge-
netic furrow. (G) Western analysis of dMyc
levels in 15 pairs of FRT80B (left lane) or 15
pairs of ago1/M(3) (right lane) third-instar lar-
val eye discs. (H) Northern analysis of
pitchoune and -Tubulin 56D transcript levels
in 4 g of total RNA from the indicated geno-
types. The difference in band intensity be-
tween adjacent lanes as determined with NIH
Image is indicated. RNA in situ analysis with
an anti-sense dMyc RNA probe shows that
the levels of dMyc transcripts in third-instar
eye discs are similar in (I) wild-type discs and
in (J) ago1/M(3) discs. A negative-control
sense dMyc RNA probe produces no detect-
able signal in wild-type discs (K), whereas the
anti-sense dMyc RNA probe readily detects
increased dMyc transcripts in pGMR-Gal4;
UAS-dMyc discs (L).
more than 95% of the disc cells are ago mutant (geno- that ago mutant cells contain more RNA than control
cells. The increase in the amount of RNA appears totype denoted ago/M(3)). The dMyc protein detected in
ago/M(3) discs also appears to have reduced mobility result from a disproportionate increase in rRNA in ago/
M(3) discs (K.H.M., unpublished observation). As a re-in SDS-PAGE, suggesting that in the absence of Ago,
dMyc accumulates in a modified form. Significantly, sult, when equal amounts (4 g) of total RNA are ana-
lyzed by Northern blotting, a control RNA (-Tubulinoverexpression of cyclin E in larval eye discs did not
detectably alter dMyc levels (data not shown), sug- 56D mRNA) is less abundant in the ago/M(3) sample
compared to FRT80B. In contrast, the level of RNA ofgesting that accumulation of dMyc protein in ago mutant
cells is not an indirect effect of the concurrent deregula- the dMyc target gene pitchoune [4, 23] is increased. If
this change were normalized to the levels of -Tubulintion of Cyclin E levels.
To determine if dMyc-dependent transcription is also 56D RNA, this would represent an approximately 3-fold
increase of pitchoune RNA in ago/M(3) discs relative toderegulated in ago cells, we examined the expression
of a dMyc target gene in ago/M(3) and FRT80B discs the wild-type (Figure 2H). These findings provide evi-
dence for increased expression of a putative dMyc tar-(Figure 2H). In three independent RNA preparations from
equal numbers of staged discs, we observed that ago get gene in ago mutant cells.
To begin to examine how ago normally functions tomutant discs contain approximately twice as much total
RNA as control discs. As ago/M(3) and FRT80B discs inhibit dMyc levels, we performed in situ analysis of
dMyc mRNA on FRT80B and ago/M(3) larval eye discsare approximately the same size and contain similar
levels of total protein (data not shown), this indicates (Figures 2I–2L). In control discs (Figure 2I), an anti-sense
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dMyc RNA probe detects dMyc expression at low levels els in the presence or absence of coexpressed AgoF
protein after treatment with the translation inhibitorthroughout the eye disc, with a stronger stripe immedi-
ately posterior to the morphogenetic furrow (arrow- cycloheximide (CHX) (Figure 3E). When dMyc is ex-
pressed alone, its levels decline rapidly after CHX treat-heads), whereas a sense dMyc RNA probe (Figure 2K)
produces no discernable staining in wild-type discs. The ment, indicating that dMyc is normally quite unstable.
In contrast, dMyc coexpressed with AgoF persistspattern and level of dMyc expression is unchanged in
ago/M(3) discs (Figure 2J). It is possible that subtle in- longer in cells after CHX addition, indicating that dMyc
is more stable when SCFAgo activity is reduced. In sup-creases in dMyc mRNA levels are below the limits of
the detection techniques used here, but it is clear that port of this, we find that treatment of cells with double-
stranded ago RNA (dsRNA) or with the proteasome in-the anti-sense dMyc RNA probe easily detects in-
creased dMyc transcripts in pGMR-Gal4;UAS-dMyc eye hibitor MG132 increases the amount of transfected
dMyc (Figure 3F) detected in cells. These data indicatediscs (Figure 2L). These data suggest that ago inhibits
dMyc accumulation largely through a posttranscrip- that dMyc is degraded via the proteasome in vivo in a
manner similar to mammalian c-Myc and that as thetional mechanism.
substrate specificity component of an SCFAgo ubiquitin-
ligase, Ago is likely to participate in this process.
Ago Binds to dMyc and Regulates Its Stability
dMyc was identified as a candidate Ago binding protein,
A Specific Role for archipelagoso we examined whether the ability of ago to regulate
in Regulating dMyc In VivodMyc involves a direct interaction between Ago and
In addition to Ago, one or more of the 23 other F boxdMyc (Figure 3). In protein extracts from Drosophila S2
proteins encoded by the Drosophila genome [24] mightcells transfected with epitope-tagged versions of Ago
also play a role in regulating dMyc levels in vivo. Of particu-and dMyc (HAAgo and FLAGdMyc), FLAGdMyc was readily
lar note are the Drosophila F box proteins Slmb anddetected in anti-HA immunoprecipitates (Figure 3A, lane
CG9772. The Slmb protein, encoded by the supernumer-2), and in the reciprocal procedure, HAAgo was readily
ary limbs (slmb) gene [25, 26], is the Drosophila proteindetected in anti-FLAG immunoprecipitates (Figure 3B,
most similar to Ago within the F box and WD repeats.lane 2). These experiments indicate that Ago and dMyc
The gene CG9772 may encode the Drosophila orthologinteract physically in S2 cells. Significantly, two mutant
of the human F box protein Skp2 (54% similarity andversions of Ago, Ago1 and Ago3, which correspond to
31% identity between CG9772-PA and Skp2 across theirmutations that deregulate dMyc levels and increase
length), which has recently been shown to regulate c-Mycgrowth in vivo, are dramatically impaired in their ability
levels in a transformed mammalian cell line [27, 28].to interact with dMyc in cells (Figure 3C, lanes 3 and 4)
To assess the relative roles of these F box familydespite being expressed at approximately the same
members in regulating endogenous dMyc levels, welevel as wild-type Ago protein (Figure 3D). Thus, as is
used double-stranded RNA interference (dsRNAi) in S2the case with the other known SCFAgo substrate, Cyclin
cells to reduce the RNA levels of ago, slmb, and CG9772E [17], the ability of Archipelago to bind dMyc protein
(Figure 4A). Reducing ago function in S2 cells by agocorrelates with its ability to downregulate dMyc levels
dsRNAi results in the stabilization and accumulation ofin vivo.
dMyc protein (Figures 4A and 4B). In contrast, despiteCoexpression of dMyc also seems to promote Ago
significant reduction in the levels of slmb and CG9772accumulation in cells (Figure 3B, lanes 3 and 4; Figure
RNAs, there is no discernible change in dMyc levels. We3C, lanes 1 and 2; Figure 4D, bottom panel, lanes 1 and
also tested whether the CG9772-PA protein (a CG97722). This increase seems more evident in forms of Ago
isoform containing the complete F box and leucine-richthat bind strongly to dMyc (data not shown) and does not
repeat domains) could bind dMyc in a manner similarappear to be a general effect of dMyc on all coexpressed
to Skp2, its putative human ortholog (Figures 4C andproteins (Figure 4D, lanes 3 and 4). However, the precise
4D). Ago and CG9772 accumulate to similar levels in themechanism underlying this effect has not been estab-
absence of coexpressed dMyc (Figure 4D, bottom panel,lished. It may involve direct dMyc-Ago binding, but it
lanes 1 and 3). However, CG9772-PA displayed verymay also be an indirect consequence of Myc’s ability
little dMyc binding activity compared to Ago (Figuresto regulate cell metabolism and translation rates.
4C and 4D, top panel). Although these data do not ruleBecause Ago and dMyc proteins interact, we tested
out a role for other F box proteins in regulating dMycif perturbing Ago function in S2 cells could modulate
levels and/or activity, they do indicate that at least indMyc levels and stability. A putative dominant-negative
S2 cells, and among the Ago, Slmb, and CG9772 pro-form of Ago that lacks the F box domain (AgoF) was
teins, only Ago is able to bind to dMyc and regulate itsconstructed. AgoF is predicted to bind target proteins
stability.via an intact WD repeat domain but to be unable to
recruit them into SCFAgo. Expression of AgoF is thus
predicted to stabilize SCFAgo targets. Coexpression of Genetic Interactions between
archipelago and dMycdMyc and AgoF in cells increases the amount of Ago-
dMyc complex recovered in coimmunoprecipitation ex- Consistent with the observed physical interaction be-
tween the Ago and dMyc proteins, we found that an agoperiments (Figure 3C, top panel, compare lanes 2 and
5) and increases the overall levels of dMyc in these cells mutation could modify dMyc mutant phenotypes. The
dMyc allele diminutive1 (dm1) is a hypomorphic viable(Figure 3C, bottom panel). To determine whether AgoF
expression alters dMyc stability, we assayed dMyc lev- mutation caused by a gypsy element insertion into the
ago Inhibits dMyc Accumulation in Drosophila
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Figure 3. Archipelago Interacts with dMyc and Regulates dMyc Levels and Stability
Immunoprecipitation-immunoblot analysis of dMyc and Ago shows that dMyc is recovered with wild-type Ago ([A], lane 2) on anti-HA agarose
beads and that Ago is recovered with dMyc ([B], lane 2) on anti-FLAG agarose beads from extracts of Drosophila S2 cells expressing HA-
tagged wild-type Ago (HAAgo) and FLAG-tagged dMyc (FLAGdMyc). (C) The Ago-dMyc interaction is disrupted by ago mutations that lead to
overgrowth in vivo (top panel, lanes 3 and 4) and is enhanced by a putative dominant-negative form of Ago that lacks the F box (top panel,
lane 5) and increases the total level of dMyc protein in cells (bottom panel, lane 5). The Ago1 protein is prematurely truncated in the WD region
and migrates more quickly than full-length Ago in SDS-PAGE. (D) Mutant and wild-type forms of Ago are expressed in S2 cells at approximately
equal levels. (E) dMyc levels in Drosophila S2 cells expressing FLAGdMyc alone (lanes 1–5) or FLAGdMyc together with the putative Archipelago
dominant-negative HAAgoF (lanes 6–10) at the indicated time points after addition of the translation inhibitor cycloheximide (CHX). dMyc
alone has a t1/2 of less than 10 min, whereas in the presence of AgoF, it is stabilized with a t1/2 of more than 30 min. (F) Levels of tagged
dMyc increase in cells after treatment with either the proteasome inhibitor MG132 or double-stranded ago RNA to reduce Ago activity. One
of two plates of pMT-FLAG-dMyc-expressing cells was treated with ago dsRNA while the other was left untreated. Each was then split in
two and incubated for an additional 3 hr with or without MG132.
first intron of the dMyc genomic locus [29, 30]. dm1 size. Thus, dm1 wings are small because they contain
fewer cells, and a 2-fold reduction in wild-type ago genehomozygous females and dm1 hemizygous males are
smaller than wild-type flies, and the females are sterile. dosage increases the size of these mutant wings by
increasing the number of normally sized cells. However,dm1 flies that are heterozygous for ago (dm1;ago1/) are
larger than dm1 flies (Figure 5A). Quantitation of this ago mutations do not rescue size defects associated
with the dMyc alleles dmP0 and dmP1 (data not shown).effect shows that heterozygosity for a mutation in ago
increases dm1 female body length by approximately These are stronger loss-of-function mutations than dm1
and reduce organism size by reducing cell size, with little12% (Figure 5C). The wings of these dm1;ago1/ adults
are also approximately 15% larger than those of dm1 effect on cell number [22]. dm1 may therefore represent a
weaker dMyc allele whose body-size phenotype remainsadults (Figure 5B). To determine whether these effects
are due to an increase in cell number, cell size, or both, sensitive to ago gene dosage.
In addition to restoring cell number in the dm1 mutantwe determined wing hair density in the relevant geno-
types (Table 1). Because each cell in the wing generates wings, reducing ago function can also ameliorate the
female fertility defect of dMyc mutant animals (Tablea single hair, hair density varies inversely with cell size.
The hair density in dm1, dm1;ago/, and wild-type wings S1 in the Supplemental Data available with this article
online). Unlike dm1;FRT80B/ females, dm1;ago1/ fe-is the same, indicating that the cells are of comparable
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Figure 4. A Specific Role for Ago in Regulating dMyc Levels and Stability
(A) The effect of treatment with the indicated dsRNAs on dMyc protein levels (as assessed by Western blotting, top panel) or on levels of
target mRNAs (as assessed by RT-PCR, bottom three panels) in Drosophila S2 cells. (B) Endogenous dMyc levels at the indicated time points
after CHX addition in untreated S2 cells or in S2 cells treated with ago dsRNA. ([C and D], top panel). Side-by-side comparison of the dMyc
binding properties of CG9772-PA and Ago by reciprocal immunoprecipitation-immunoblot analysis from S2 cells transfected with equal
amounts of the indicated plasmids. ([D], bottom panel) Anti-HA immunoblot of S2 cell extracts expressing HA-tagged versions of Ago and
CG9772-PA. The HAAgo and HACG9772-PA bands are indicated by arrowheads.
males lay eggs that can give rise to viable larvae. In Discussion
addition, dm1/dmPG45;ago/ females [31] are approxi-
mately 10-fold more fertile than dm1/dmPG45;FRT80B/ We have shown that the F box-containing protein Ago,
which functions as the substrate-specificity subunit offemales, which normally show a 2%–3% egg hatching
rate. These data indicate that, in addition to modifying an SCFAgo ubiquitin ligase, regulates the levels of the
growth-promoting transcription factor dMyc in devel-dMyc organ and organism size phenotypes, ago is also
an antagonist of dMyc in the female germline. oping Drosophila tissues. This regulation appears to
occur via a posttranscriptional mechanism that involvesConsistent with a role for Ago in inhibiting dMyc, ago
expression retards organ growth. Expression of an a direct Ago-dMyc interaction that modulates dMyc sta-
bility. dMyc accumulates in ago mutant cells and likelyN-terminally truncated ago cDNA that contains an intact
F box domain and WD repeat region in the posterior contributes to their increased growth.
compartment of the wing decreases its size by approxi-
mately 35% (Figure 5D). Hair density measurements in- Myc and Cyclin E Share a Putative
Ago Interaction Motifdicate that cells in the ago-expressing compartment
are approximately 32% smaller than controls (Table 1), The WD repeat domain of Ago interacts with Cyclin E
[17–19], and we now show that it also binds dMyc. Thesuggesting that the reduction in compartment size is
largely an effect of reduced cell size. Thus, overproduc- optimal binding site for the WD domain of S. cerevisiae
Cdc4, the yeast ortholog of Ago, has been determinedtion of an N-terminally truncated version of Ago in the
developing wing mimics the effect of dMyc mutations to be I/L-I/L/P-pT-P-P, in which the central threonine
residue is phosphorylated [32]. Human Cyclin E, Dro-and inhibits growth.
ago Inhibits dMyc Accumulation in Drosophila
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Table 1. Effect of archipelago on Cell Size in the Adult Wing
Number of Hairs Average Cell
Genotype in Areaa Area (m2)
wildtype (y w1118) 197  5.3 (n  8) 159
y w dm1;FRT80B/ 202  6.4 (n  8) 155
y w dm1;FRT80B ago1/ 197  5.6 (n  6) 159
engrailed-Gal4 199  5.0 (n  4) 158
engrailed-Gal4;UAS-agoN 291  2.5 (n  4) 108
a For determination of relative cell size, wings from adult female flies
of the indicated genotypes were examined for trichome density. The
number of trichomes was counted in a fixed area (boxed in Figure
5B) adjacent to the posterior cross vein.
which the central threonine is often replaced by a serine,
and many of the flanking residues deviate from those
in the consensus sequence. Importantly, these putative
sites do retain a conserved S/T residue at position 4
(asterisk). The equivalent 4 serine in human Cyclin E
(S384) has recently been shown to be required for the
ubiquitination of Cyclin E [33] and may therefore repre-
sent an important feature of the putative Ago binding
motif. The presence of multiple Ago binding sites in
dMyc versus the single well-conserved site in c-Myc
might indicate that although both proteins are targeted
for degradation by orthologous F box proteins, the kinet-
ics of degradation of the two Myc proteins may be dif-
ferent.
The array of apparently suboptimal sites in dMyc re-
sembles the situation in S. cerevisiae Sic1, in which nine
low-affinity sites are able to cooperatively mediate a
stable interaction with Cdc4 [32, 34]. Indeed, as is the
case with Sic1, mutating a single putative phosphoryla-
tion site in dMyc does not alter its Ago binding properties
(Figure S1). In contrast, for human Cyclin E and c-Myc,
Figure 5. An archipelago Allele Modifies dMyc Organism-Size De-
fects, and an archipelago Transgene Reduces Compartment Size
in the Wing
(A) An archipelago mutant chromosome partially suppresses the
small organism size of the viable, hypomorphic dMyc allele dm1 in
both females ([A], top) and males (bottom) compared to the parental
FRT80B chromosome. (B) Overlay of adult wings shows that
dm1;ago/ wings are larger than dm1 wings. The inset square indi-
cates the region of the wing used for cell counts in Table 1. (C)
Quantitation of body-length in females of the indicated genotypes
(p  0.05). (D) Compared to control wings carrying only the en-
Figure 6. Myc and Cyclin E Share a Putative Ago Interaction Motifgrailed-Gal4 driver, adult wings expressing the carboxy-terminal
660 amino acids of Ago in the posterior half of the wing (engrailed- (A) The location of candidate Ago interaction motifs (black boxes) in
Gal4;UAS-agoN) display reduced posterior compartment size. A human Cyclin E, human c-Myc, Drosophila Cyclin E, and Drosophila
dotted line indicates the approximate border between the posterior Myc.
and anterior compartments of the wing. (B) Amino acid comparison between these motifs suggests that a
single high-affinity phospho-epitope is conserved in human Cyclin
E, human c-Myc, and fly Cyclin E and that multiple phospho-epitopesophila Cyclin E, and human c-Myc all have a single,
sites may be present in dMyc. Identical (black boxes) and similar
well-conserved version of this site, whose central fea- (open boxes) residues are indicated. The central S/T residue is
ture is an L-L-T-P-P motif (Figure 6). dMyc contains marked by an arrowhead, and the conserved S/T residue at position
4 is marked by an asterisk.seven copies of a degenerate version of this site, in
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the predicted Ago interaction site lies within a domain notype of these tumors may reflect the additive effect
of activating all of these pathways that are normallypreviously shown to be required for their ubiquitination
and degradation [9, 10, 35, 36]. Furthermore, missense inhibited by Ago.
mutations of the central threonine in the Ago interaction
motif are the most frequent c-Myc mutations in Burkitt’s Experimental Procedures
lymphoma [1] and stabilize c-Myc in cells [9, 10], sug-
gesting that Ago-dependent degradation of c-Myc is Drosophila Genetics
Unless indicated, flies were maintained at 25C. To generate “ago/perturbed in these cancers.
M(3)” discs, the 3L Minute P[mini-w]Rpl141 (Bloomington Stock Cen-
ter) was recombined onto the FRT80B chromosome, and y w eyFLP;
FRT80B P[mini-w]Rpl141/TM6B virgin females were crossed toRegulation of Growth and Cell Proliferation by ago
w;FRT80B ago1 males to generate y w eyFLP/;FRT80B ago1/
ago mutant cells grow more quickly than their wild-type FRT80B P[mini-w]Rpl141 animals with “ago/M(3)” eye discs. Other
neighbors, but they maintain their normal size by an genotypes used were as follows: w;FRT80B ago1/TM6B, y w eyFLP;
apparent acceleration of the cell cycle. This differs con- FRT80B P[mini-w;arm-lacZ], y w eyFLP;FRT80B P[mini-w] P[Ubi-
GFP]/TM6B, y w hsFLP;FRT80B P[mini-w] P[Ubi-GFP]/TM6B, dm1/siderably from the phenotype elicited by overexpression
FM7c; FRT80B ago1/TM6B, dm1/FM7c; FRT80B/TM6B, and dmPG45/of either dMyc or Cyclin E. Increased expression of dMyc
FM7c. dMyc stocks were a gift of R. Eisenman.results in increased growth that manifests as an increase
in cell size without any change in the duration of the
Molecular Biologycell cycle [22]. dMyc also promotes S phase entry, possi-
Drosophila Myc copurified with TAP(tandem affinity purification)-bly as a consequence of the increased growth. In-
tagged Ago expressed in Drosophila Kc cells [42, 43]. Cell extraction,creased expression of Cyclin E has no effect on growth
purification, and mass-spectrometric identification of copurifying
but promotes S phase entry [21]. It also results in, at proteins (Taplin Mass Spectrometry Facility, Harvard Medical
best, a modest acceleration of the cell cycle. Thus, the School) were performed via procedures modified for Drosophila
cell cycle acceleration observed in ago mutant cells is cells [44]. dMyc was also recovered in a standard two-hybrid screen
in which approximately 5.0 	 106 colonies of a random-primed Dro-not easily explained by the elevated level of either dMyc
sophila 0–24 hr embryonic cDNA library were sceened with a cDNAor Cyclin E. Both dMyc and Cyclin E promote S phase
corresponding to amino acids 681–1325 of Drosophila Ago fusedentry but maintain the normal duration of the cell cycle
in-frame to the LexA DNA binding domain [45].
by apparently lengthening the S and G2 phases, respec- For expression in cells, full-length archipelago, CG9772-PA, and
tively. Thus, it seems likely that ago loss also affects a dMyc open reading frames were amino-terminally tagged with either
regulatory protein that promotes the G2-M transition. HA (ago and CG9772-PA) or Flag (dMyc) tags and cloned into pMT
expression vectors (Invitrogen). HAAgo1 and HAAgo3 carry point muta-Such a regulator could either be a direct substrate of
tions corresponding to ago alleles described previously [17]. pMT-SCFAgo or may be regulated indirectly.
HA-agoF was constructed from pMT-HA-ago with the QuikChangeInterestingly, both Ago targets identified to date,
Kit (Stratagene) for removal of codons 895–923, representing the
Cyclin E and dMyc, are required for imaginal-disc growth. core Ago F box. UAS-agoN was constructed by insertion of the
We have also observed that signaling via the Notch C-terminal 660 codons of the archipelago cDNA (designated agoN)
receptor is increased in ago clones (data not shown), into the EcoR1 site of the pUAST vector.
as assessed by the activity of a reporter gene fused to
the Enhancer of split m promoter [37]. Notch signaling Cell Culture and Transfection
has been shown to promote imaginal-disc growth at Drosophila S2 cells were maintained at 25C in standard Schneider
least in part by a non-cell-autonomous pathway [38]. cell medium (JRH Biosciences) supplemented with 10% fetal calf
serum. Equal numbers of cells were transfected as indicated withBecause cyclin E, dMyc, and Notch all participate in
3 g of each expression vector per 10 cm plate via the Effectenetissue growth via increases in cell number and/or cell
reagent (Qiagen). Transfections were done in parallel, and DNAmass, Ago may represent a way to coordinately regulate
amounts were normalized with empty vector. The pIE14-GFP ex-these pathways by a common degradation mechanism. pression vector (Novagen) was used in some experiments (0.1 g)
Thus, increased Ago levels would be expected to impair to monitor transfection efficiency. CuSO4 (0.35 mM) was added to
tissue growth, and decreased levels would facilitate tis- cells 24 hr after transfection to induce protein expression for 12 hr
prior to analysis. Transfection of dsRNA-treated cells was performedsue growth, via multiple pathways. Because we have
as described above 3 days after the addition of dsRNA (see below),previously shown that ago transcription is patterned in
with the addition of 3 g of dsRNA to the transfection mix. Afterthe eye imaginal disc [17], ago may function to link pat-
CuSO4 addition, cells were treated where indicated with the protea-terning signals with the activity of these growth-promot- some inhibitor MG132 (50 M; Calbiochem) for 3 hr prior to analysis.
ing pathways.
The ability of ago to regulate multiple pathways that
RNA Interference, In Situ, and Northern Analysisfunction in growing cells has implications for under-
Double-stranded RNA interference treatments were carried out asstanding the role of its human ortholog (Fbw7/hCDC4) as
described in [46], and cells were harvested for analysis 5 days later.
a tumor suppressor gene. We and others have identified The RiboMax-T7 system (Promega) was used to prepare dsRNAs
mutations in Fbw7/hCDC4 in cancer cell lines [17, 18], from PCR products generated from primer pairs specific to ago,
CG9772, and slmb (see Supplemental Data). Analysis of ago, slmb,and more recently, mutations have been identified in
and CG9772 mRNA levels in dsRNA-treated cells was carried outFbw7/hCDC4 in endometrial and colorectal tumors [39,
with the Titanium One-Step RT-PCR Kit (BD Biosciences). RNA for40]. These tumors are likely to have elevated levels of
Northern blotting was prepared with the Trizol Reagent (Gibco-BRL).Cyclin E. In light of the data presented here, they are
Blots were hybridized with pitchoune or -Tubulin 56D 32P-labeled
predicted to have high levels of the oncoprotein c-Myc DNA probes in ULTRAhyb hybridization buffer (Ambion). For RNA
and increased Notch activity, which has also been impli- in situ analysis, the sense and anti-sense dMyc RNA probes were
derived from the full-length dMyc open-reading frame.cated in human cancers [41]. Thus, the neoplastic phe-
ago Inhibits dMyc Accumulation in Drosophila
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Immunoprecipitation and Western Blotting c-myc oncogene driven by immunoglobulin enhancers induces
lymphoid malignancy in transgenic mice. Nature 318, 533–538.Cell extracts were prepared in a lysis buffer containing 0.4% NP-
40 and protease inhibitors. Equal amounts of extracted proteins 7. Langenau, D.M., Traver, D., Ferrando, A.A., Kutok, J.L., Aster,
J.C., Kanki, J.P., Lin, S., Prochownik, E., Trede, N.S., Zon, L.I., etwere then incubated for 1–2 hr with anti-HA or anti-Flag agarose
(Sigma) and washed three times with lysis buffer, and the samples al. (2003). Myc-induced T cell leukemia in transgenic zebrafish.
Science 299, 887–890.were resolved by 7.5% SDS-PAGE prior to Western blotting (WB)
with anti-HA or anti-FLAG antibodies (1:5000; Sigma) or anti-dMyc 8. Stewart, T.A., Pattengale, P.K., and Leder, P. (1984). Spontane-
ous mammary adenocarcinomas in transgenic mice that carryantibody (1:20; mouse monoclonal P4C4-b10).
and express MTV/myc fusion genes. Cell 38, 627–637.
9. Salghetti, S.E., Kim, S.Y., and Tansey, W.P. (1999). DestructionMicroscopy, Immunohistochemistry, and Flow Cytometry
of Myc by ubiquitin-mediated proteolysis: cancer-associatedAdult eyes were photographed while submerged in mineral oil.
and transforming mutations stabilize Myc. EMBO J. 18, 717–726.Whole-mount flies and wings were prepared and photographed via
10. Gregory, M.A., and Hann, S.R. (2000). c-Myc proteolysis by thestandard techniques. For immunofluorescence, discs were fixed
ubiquitin-proteasome pathway: stabilization of c-Myc in Bur-and stained as described previously [17]. The P4C4-b10 antibody
kitt’s lymphoma cells. Mol. Cell. Biol. 20, 2423–2435.was used undiluted. Anti--galactosidase rabbit polyclonal antibody
11. Henriksson, M., Bakardjiev, A., Klein, G., and Luscher, B. (1993).(Cappel), anti-rabbit Cy5, and anti-mouse Cy3 (Jackson Laboratories)
Phosphorylation sites mapping in the N-terminal domain ofwere used at 1:100. FACS and loss-of-function wing clone analysis
c-myc modulate its transforming potential. Oncogene 8, 3199–were performed as described previously [47]. In brief, clones were
3209.induced by a 30 min heat-shock at 37C 48 hr after egg deposition
12. Lutterbach, B., and Hann, S.R. (1994). Hierarchical phosphoryla-(AED), and wing discs were dissected for analysis 48, 72, 96, and 120
tion at N-terminal transformation-sensitive sites in c-Myc pro-hr later. The genotypes were y w hsFLP/;FRT80B/FRT80B Pmini-w]
tein is regulated by mitogens and in mitosis. Mol. Cell. Biol. 14,P[Ubi-GFP] and y w hsFLP/; FRT80B ago1/FRT80B Pmini-w] P[Ubi-
5510–5522.GFP]. The doubling-times of the ago, FRT80B and GFP tester (con-
13. Pulverer, B.J., Fisher, C., Vousden, K., Littlewood, T., Evan, G.,trol) chromosomes were calculated as described previously [22]
and Woodgett, J.R. (1994). Site-specific modulation of c-Mycwith cell-count data collected 72 hr after induction. The FRT80B
cotransformation by residues phosphorylated in vivo. Onco-and control chromosomes gave similar results (data not shown).
gene 9, 59–70.
14. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins,Supplemental Data
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